drugset
drugset / Trial / NCT04583358

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

NCT04583358 ↗

Phase 2 Unknown 105 enrolled Applied Molecular Transport
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Timeline

Start
2020-08-26
Primary completion
2022-11-30
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator VIMEKOFUSP Protein / enzyme biologic — Oral

Indications

ulcerative colitis